Skip to content

Assessment of Serum Asprosin Level in Male Patients With Acne Vulgaris

Assessment of Serum Asprosin Level in Male Patients With Acne Vulgaris

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05471388
Enrollment
72
Registered
2022-07-22
Start date
2022-07-18
Completion date
2023-01-18
Last updated
2022-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

Asprosin

Brief summary

Subject of interest is to evaluate serum level of asprosin in male patients with acne vulgaris, demonstrate the relation between acne vulgaris severity and level of asprosin in these patients & the relation between metabolic syndrome in acne vulgaris and level of asprosin.

Interventions

DIAGNOSTIC_TESTserum asprosin

assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Acne vulgaris male patients (\>18 years) will be included.

Exclusion criteria

* Age \<18 years. * Females. * Patients with other inflammatory skin disorders. * Patients with associated systemic diseases. * Current or previous treatment with isotretinoin in the last 3 month ,anti-inflammatory drugs, systemic antibiotics, androgen or anti androgen therapy, and steroid therapy). * Patients known on treatment of diabetes, hypertension and dyslipidemia. * Athletes. * Patient refusal.

Design outcomes

Primary

MeasureTime frameDescription
Assess serum asprosin level in male patients with acne vulgaris.6 monthsAssess serum asprosin level in male patients with acne vulgaris.

Countries

Egypt

Contacts

Primary ContactEsraa A Hamoda, resident
esraaabdelazeem@med.sohag.edu.eg01007911703
Backup ContactSoha H Aboeldahab, assisstant professor
01094235561

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026